Rezolute (RZLT) Receivables - Notes (2012 - 2013)
Rezolute recorded quarterly Receivables - Notes of $163829.0 in Q1 2013, down 80.32% quarter-over-quarter from $832454.0 in Q2 2012.
Rezolute's Receivables - Notes history runs 2 years deep, the most recent figure standing at $163829.0 for Q1 2013.
- In Q1 2013, Receivables - Notes changed N/A year-over-year to $163829.0; the TTM figure through Mar 2013 stood at $163829.0 (changed N/A YoY), while the FY2012 annual figure was $832454.0, changed N/A from the prior year.
- Receivables - Notes came in at $163829.0 for Q1 2013 at Rezolute, down from $832454.0 in the prior quarter.
- In the past five years, Receivables - Notes ranged from a high of $832454.0 in Q2 2012 to a low of $163829.0 in Q1 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 163,829.00 |
| Jun 30, 2012 | 832,454.00 |